Product Name:
RIPK1-pY384
Product Number:
ab-pk795
Target Full Name: Receptor-interacting protein-serine kinase 1
Target Alias: RIK1; RIP
Product Type Specific: Protein kinase phosphosite-specific antibody
Antibody Code: PK795
Antibody Target Type: Phosphosite-specific
Antibody Phosphosite: Y384
Protein UniProt: Q13546
Protein SigNET: Q13546
Antibody Type: Polyclonal
Antibody Host Species: Rabbit
Antibody Immunogen Source: Human RIPK1 sequence peptide Cat. No.: PE-04APH99
Antibody Immunogen Sequence: EAN(pY)HLY(bA)C
Antibody Immunogen Description: Corresponds to amino acid residues E381 to Y387; In the region between the kinase catalytic and RHIM domains. This is a major in vivo phosphorylation site in RIPK1.
Production Method: Corresponds to amino acid residues E381 to Y387; In the region between the kinase catalytic and RHIM domains. This is a major in vivo phosphorylation site in RIPK1.
Antibody Modification: Protein kinase phosphosite-specific antibody
Antibody Concentration: 1 mg/ml
Storage Buffer: Phosphate buffered saline pH 7.4, 0.05% Thimerasol
Storage Conditions: For long term storage, keep frozen at -40°C or lower. Stock solution can be kept at +4°C for more than 3 months. Avoid repeated freeze-thaw cycles.
Product Use: Western blotting | Antibody microarray
Antibody Dilution Recommended: 2 µg/ml for immunoblotting
Antibody Potency: Very strong immunoreactivity with immunogen peptide on dot blots.
Antibody Species Reactivity: Human
Antibody Positive Control: The observed molecular mass of the processed target protein on SDS-PAGE gels is reported to be around 75-80 kDa.
Antibody Specificity: Very high
Antibody Cross Reactivity: No significant cross-reactive proteins detected in HepG2 and T98G cells.
Related Product 1: RIPK1-pY384 blocking peptide
Scientific Background: RIPK1 (RIP) is a protein-serine/threonine kinase of the TKL group and RIPK family. It has a role in inducing inflammation and necroptosis (programmed necrosis). RIPK1 has also been noted to function in the initial TLR3 recognition of dsRNA in a viral infection. A S161A mutation has been noted to decrease kinase phosphotransferase activity of RIPK1. A S161E mutation has no effect on autophosphorylation of RIPK1. Caspase-8-mediated RIPK1 cleavage is impaired through a D324K mutation. NF-kB induction through RIPK1 can be inhibited via a K377R mutation. The phosphotransferase activity of RIPK1 and its NF-kB activation are, surprisingly, not essential for the anti-apoptotic function of this protein in epithelial tissues.
